
The US Food and Drug Administration has cleared Medtronic’s Hugo robotic-assisted surgery (RAS) system for general surgery, Medtronic announced on 17 November 2026. The expanded 510(k) clearance moves Hugo beyond the urology indication it received in December 2025, and it matters to surgical-research programmes, academic medical centres and device trial teams because the registered Hugo studies now sit beside a wider US label.
What happened
In a release datelined Galway, Ireland, on 17 November 2026, Medtronic said the FDA had granted an expanded 510(k) clearance for the Hugo RAS system in general surgery. The release says the clearance “covers all upper abdominal general surgical procedures,” and lists cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection as examples, introduced with the words “including but not limited to.” For the lower abdomen, it names two procedures: inguinal hernia repair and appendectomy.
MedTech Dive, reporting the same day, described the clearance in the same terms and noted that Hugo’s first US clearance, in December 2025, covered only urologic procedures such as prostate removal. It called that first clearance the first time a large medical-technology company had brought a robotic soft-tissue platform to the US market since Intuitive launched the da Vinci system in 2000.
Key details
| Item | What the sources report |
|---|---|
| Regulatory route | Expanded 510(k) clearance; the earlier urology clearance is FDA record K250725 (Hugo RAS System, applicant Covidien, LLC, decision 3 December 2025, product code SCV, review panel General & Plastic Surgery) |
| Upper abdominal scope | All upper abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia and small bowel resection |
| Lower abdominal scope | Inguinal hernia repair and appendectomy |
| Market size cited by Medtronic | About 3.5 million US surgeries a year, “more than half of all soft-tissue procedures performed in the country each year” |
| Not part of the US clearance | The Sentire surgical system, which Medtronic distributes only in select markets outside the US |
Medtronic describes Hugo as modular, so a team can use only the robotic arms a procedure needs, with an open console that connects the surgeon with the operating-room team. The company’s LigaSure RAS Maryland instrument is available for robotic cases. The 3.5 million figure is Medtronic’s own market estimate, not a clinical result, and the release does not report study outcomes for the newly cleared procedures.
Background: how the clearance was built
Medtronic announced on 3 June 2026 that it had filed 510(k) submissions to extend Hugo into general and gynecologic surgery, with hernia repair named as part of the general-surgery request, according to MedTech Dive’s report of 4 June 2026. The same report quotes chief executive Geoff Martha saying on the earnings call that the company applied for the additional indications in late April. Bariatric News reported the same filings and noted that Hugo is already used for these procedures in major markets outside the US.
The FDA’s public record for the December 2025 urology clearance links to a ClinicalTrials.gov entry, NCT05696444, titled Medtronic Hugo Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO). The registry shows a Medtronic-sponsored, single-arm, interventional study that began on 14 December 2022 and reached primary completion on 10 October 2024, with 144 participants enrolled at six listed sites. Its primary effectiveness endpoint is surgical success, defined as the procedure not going into conversion, and its primary safety endpoint is the rate of complications of Clavien-Dindo Grade III to V within 30 days of the procedure.
The registered hernia study
For the general-surgery side, the registry holds a Medtronic-sponsored study of Hugo in hernia repair, NCT06445504, titled Enable Hernia Repair. Medtronic’s release does not name the study behind the new clearance, so this section describes what the public record shows rather than linking the two. It is a prospective, multicentre, single-arm pivotal study of inguinal and ventral hernia repair, planned at up to ten US sites with 192 participants and two years of follow-up. The registry lists seven sites, including Tampa General Hospital, the University of Illinois Chicago, the University at Buffalo, Duke University, Cleveland Clinic, UT Health in Houston and Bon Secours in Newport News, and records an actual enrolment of 206.
It started on 8 April 2024, reached primary completion on 19 March 2025, and is listed as active, not recruiting, with an estimated overall completion of March 2027. Results were posted on 4 May 2026. The primary effectiveness endpoint is surgical success, defined as no conversion to laparoscopic or open surgery or to another robotic system; the posted result lists 193 participants for that measure. The primary safety endpoint is the rate of participants with a surgical site event from first incision through 30 days. The posted counts are 0 of 92 inguinal hernia participants and 2 of 94 ventral hernia participants. A secondary endpoint, participants with complications within 30 days, shows 33 of 94 in the inguinal group and 40 of 94 in the ventral group. Eligible adults had a primary or incisional ventral hernia, with combined defects under 10 cm, or an inguinal hernia, and could be candidates for robotic, laparoscopic or open repair.
Reaction
Matt Anderson, senior vice president and president of Medtronic’s Surgical business, said in the release: “Hugo expands choice with a practical option to help hospitals address capacity and access challenges.” Dr. Francesco Bianco, a surgeon at UI Health and professor of surgery at the University of Illinois College of Medicine, said: “Expanding our robotic-assisted surgical capabilities with the Hugo RAS system allows us to offer additional treatment options.”
MedTech Dive placed the clearance in a crowded field. Johnson & Johnson received FDA authorization in July 2026 for its Ottava robot in general surgery, and Stryker announced last month an agreement to distribute CMR Surgical’s Versius soft-tissue robot in the US. Intuitive’s da Vinci remains the longstanding incumbent. In its June report, MedTech Dive cited Intuitive’s SEC filing, which shows US surgeons performed about 2 million da Vinci procedures in the prior year, of which roughly 1.25 million were general surgery.
What it means for researchers, universities and research offices
For device trial teams, the pattern in the public record is a single-arm pivotal design with surgical success and a 30-day safety measure as co-primary endpoints, run at a small number of US academic and hospital sites. A 510(k) pathway rests on substantial equivalence to a predicate, so the clinical studies registered for Hugo are performance and safety studies rather than randomised comparisons against other robots; readers who need the detail of what a 510(k) contains can start with the casrai guides on the FDA 510(k) premarket notification and on reading a 510(k) summary.
For surgical-research programmes at academic medical centres, a cleared general-surgery indication changes what can be studied without an investigational device exemption. Comparative-effectiveness work, learning-curve studies and registry studies on cleared use generally proceed under ordinary institutional review board oversight, while research on a use outside the cleared indications can require an exemption; the casrai guide to the investigational device exemption explains when one applies. Because the upper abdominal list is described as “including but not limited to,” research offices should read the indications for use in the FDA record itself, not the press summaries, before writing a protocol or a device-use agreement.
Registration and results reporting also matter here. The Hugo hernia study shows results posted to the registry about 13 months after primary completion, which is the kind of public evidence trial teams and sponsors can examine; the casrai pages on ClinicalTrials.gov and on medical device clinical trials cover the registration duties that apply.
What happens next
Medtronic says Hugo is already in clinical use at a growing number of US health systems and hospitals, that Hugo procedure growth is more than twice the robotic surgery market, and that it expects Hugo to pass 50,000 procedures by the end of its fiscal year. General surgery is now Hugo’s fastest-growing specialty outside the US, ahead of urology and gynecology. The June filing also covered gynecologic surgery; the November announcement concerns general surgery only. The Enable Hernia Repair record shows follow-up continuing, with an estimated overall completion of March 2027.
Sources
- Medtronic, Medtronic announces FDA clearance of general surgery procedures for the Hugo RAS system, 17 November 2026
- MedTech Dive (Susan Kelly), Medtronic’s Hugo robot gets expanded FDA clearance in general surgery, 17 November 2026
- MedTech Dive (Nick Paul Taylor), Medtronic seeks clearance for Hugo surgical robot in more indications, 4 June 2026
- Bariatric News, Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery, 3 June 2026
- US Food and Drug Administration, 510(k) record K250725, Hugo RAS System, decision 3 December 2025
- ClinicalTrials.gov, NCT06445504, Enable Hernia Repair, last update 4 May 2026
- ClinicalTrials.gov, NCT05696444, Expand URO, last update 3 November 2026







